<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391478</url>
  </required_header>
  <id_info>
    <org_study_id>NCT 30</org_study_id>
    <nct_id>NCT04391478</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension</brief_title>
  <acronym>ESMPPHTN</acronym>
  <official_title>Milrinone Versus Sildenafil in Treatment of PPHN in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rania Ali El-Farrash</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of milrinone versus sildenafil in treatment of neonates with persistent
      pulmonary hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 neonates with PPHN, met inclusion criteria, randomly assigned to 2 groups, each includes
      20, first group received intravenous milrinone and second group received nasogastric
      sildenafil. both groups receive other supportive care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of milrinone versus sildenafil in treatment of PPHN</measure>
    <time_frame>6 - 12 months</time_frame>
    <description>effect on oxygenation index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>final outcome</measure>
    <time_frame>6 - 12 months</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>6-12 months</time_frame>
    <description>Bleeding (e.g pulmonary hemorrhage) that is believed to be attributed to medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation</measure>
    <time_frame>6-12 months</time_frame>
    <description>total duration of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory settings</measure>
    <time_frame>6-12 months</time_frame>
    <description>highest ventilator settings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Persistent Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>milrinone lactate, 1mg/ml, for intra venous use only</description>
    <arm_group_label>milrinone</arm_group_label>
    <other_name>primacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube</description>
    <arm_group_label>sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age &gt;34 weeks

          -  postnatal age &lt;10 days

        Exclusion Criteria:

          -  neonates with congenital heart disease

          -  neonates with congenital diaphragmatic hernia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Rania Ali El-Farrash</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

